Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Ninth International Symposium on Hereditary Breast and Ovarian Cancer

Ninth International Symposium on Hereditary Breast and Ovarian Cancer Familial Cancer https://doi.org/10.1007/s10689-023-00332-5 AB STRACTS Ninth International Symposium on Hereditary Breast and Ovarian Cancer May 2–5, 2023 – Centre Mont-Royal, Montre ´al, Que ´bec, Canada Springer Nature B.V. 2023 of Gynecologic Oncology, Dept of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, United States; Presented by Advanced Clinical Biosystems Research Institute, Smidt Heart Hereditary Breast and Ovarian Cancer Foundation Institute, Dept of Biomedical Sciences, Cedars-Sinai, Los Angeles, in collaboration with CA, United States; Samuel Oschin Comprehensive Cancer Institute, Program in Cancer Genetics, McGill University Cedars-Sinai Medical Center, Los Angeles, California, United States High Grade Serous Ovarian Cancer (HGSOC) is typically diagnosed at late stage and most patients progress through tumor recurrence PROFFERED PAPERS events, eventually developing chemoresistance. To identify the genomic changes that underlie chemoresistance in HGSOC we per- S2-PP1: The genomic landscape of high grade serous formed whole genome sequencing (WGS), ultra-deep RNA-Seq, ovarian tumors is defined by loss of BRCA1 whole genome bisulfate sequencing (WGBS) and proteomics in paired chemotherapy naı ¨ve primary and recurrent tumors from 34 and BRCA2 throughout chemoresistance and relapse patients (11 BRCA1/2 germline carriers (BRCA ?); 25 patients without germline BRCA1/2 deleterious variants (BRCA-)). 1 2 2 1 Nicole Gull , http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Familial Cancer Springer Journals

Ninth International Symposium on Hereditary Breast and Ovarian Cancer

Familial Cancer , Volume 22 (3) – Jul 1, 2023
Download PDF
53 pages

Loading next page...
 
/lp/springer-journals/ninth-international-symposium-on-hereditary-breast-and-ovarian-cancer-hUq6Kzyj3c
Publisher
Springer Journals
Copyright
Copyright © Springer Nature B.V. 2023
ISSN
1389-9600
eISSN
1573-7292
DOI
10.1007/s10689-023-00332-5
Publisher site
See Article on Publisher Site

Abstract

Familial Cancer https://doi.org/10.1007/s10689-023-00332-5 AB STRACTS Ninth International Symposium on Hereditary Breast and Ovarian Cancer May 2–5, 2023 – Centre Mont-Royal, Montre ´al, Que ´bec, Canada Springer Nature B.V. 2023 of Gynecologic Oncology, Dept of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, United States; Presented by Advanced Clinical Biosystems Research Institute, Smidt Heart Hereditary Breast and Ovarian Cancer Foundation Institute, Dept of Biomedical Sciences, Cedars-Sinai, Los Angeles, in collaboration with CA, United States; Samuel Oschin Comprehensive Cancer Institute, Program in Cancer Genetics, McGill University Cedars-Sinai Medical Center, Los Angeles, California, United States High Grade Serous Ovarian Cancer (HGSOC) is typically diagnosed at late stage and most patients progress through tumor recurrence PROFFERED PAPERS events, eventually developing chemoresistance. To identify the genomic changes that underlie chemoresistance in HGSOC we per- S2-PP1: The genomic landscape of high grade serous formed whole genome sequencing (WGS), ultra-deep RNA-Seq, ovarian tumors is defined by loss of BRCA1 whole genome bisulfate sequencing (WGBS) and proteomics in paired chemotherapy naı ¨ve primary and recurrent tumors from 34 and BRCA2 throughout chemoresistance and relapse patients (11 BRCA1/2 germline carriers (BRCA ?); 25 patients without germline BRCA1/2 deleterious variants (BRCA-)). 1 2 2 1 Nicole Gull ,

Journal

Familial Cancer – Springer Journals

Published: Jul 1, 2023

There are no references for this article.